Bacteria-Killing Viruses Get Their First International Rulebook

Keypoints:

• The German Society for Infectious Diseases led the first international guidelines for personalized phage therapy
• The effort involved 20 professional organizations, 18 international experts and two patient advocacy groups
• It produced more than 60 recommendations, published in Nature Medicine
• In a Belgian series of 100 patients, 77% improved and targeted bacteria disappeared in 61%
• Frankfurt University Medical Center has treated ten patients since February 2026

Antibiotic resistance keeps making infections harder to treat. Doctors are now looking at bacteriophages, or phages, which are viruses that infect and destroy bacteria. An international team has published the first coordinated clinical guidelines for using them as personalized treatment. The guidelines appear in Nature Medicine.

The group covered 20 professional organizations, 18 experts including regulators and two patient groups. Their 60-plus recommendations cover how phages are selected, tested, manufactured, given and monitored. Until now, doctors had no shared international framework for these steps.

The "personalized" part matters because phages are picky. Many antibiotics hit a broad range of bacteria, but a phage typically targets one species or even a single strain. Labs must therefore run a "phage match" test before treatment. Bacteria can change their susceptibility during an infection, so speed matters.

The idea is old, which adds some context. Phage therapy faded after antibiotics developed rapidly in the 1930s. Rising resistance is bringing it back into clinics. At Frankfurt University Medical Center, ten patients have been treated since February 2026, including for Pseudomonas aeruginosa and Staphylococcus aureus. Treatment can be given intravenously, by inhalation, as a nasal spray or through a sterile hydrogel.

In a Belgian case series of 100 people, 77 percent improved and the targeted bacteria became undetectable in 61 percent. Those numbers are encouraging, but they come with limits. Observational data cannot show that phages caused the improvement, and controlled trials are still missing. The guidelines do not recommend phage therapy as a routine treatment. They point to cases where standard options have failed or cannot be used safely.

Dr. Silvia Würstle, the corresponding author, says the guidelines give physicians, pharmacists and regulators a common framework. Shared standards are often the unglamorous step that turns a promising lab idea into something hospitals can offer.